Why the obesity pipeline is bifurcating around mechanism
The obesity therapeutics market is undergoing rapid transformation driven by incretin-based pharmacology, with GLP-1 receptor agonists now established as the dominant standard of care and next-generation dual and triple agonists entering late-stage development. The central competitive question for R&D and IP teams is no longer whether incretin therapy works — it is which receptor combination, at what selectivity ratio, and via which formulation strategy will define the next wave of differentiated products.
Two programs — CT-388 from Roche (via its acquisition of Carmot Therapeutics) and petrelintide from Zealand Pharma — represent the clearest examples of distinct mechanistic bets in this bifurcating landscape. CT-388 pursues GLP-1 and GIP receptor co-agonism; petrelintide pursues amylin and calcitonin receptor agonism. These are not incremental variations on the same target — they are fundamentally different hypotheses about which neuroendocrine pathways will deliver superior weight loss outcomes with acceptable tolerability.
For IP professionals, R&D strategists, and drug discovery teams, understanding the patent architecture, clinical identifiers, and competitive positioning of these programs requires navigating multiple data sources: patent filings at WIPO, clinical registrations, conference abstracts, and corporate disclosures. This article maps the landscape as it stands and identifies the intelligence signals that matter most.
The obesity therapeutics market is undergoing rapid transformation driven by incretin-based pharmacology, with GLP-1 receptor agonists now established and next-generation dual and triple agonists entering late-stage development. CT-388 (Carmot Therapeutics/Roche) and petrelintide (Zealand Pharma) represent distinct mechanistic bets — GLP-1/GIP dual agonism and amylin receptor agonism, respectively — competing for differentiated positioning in a market defined by tirzepatide and semaglutide.
CT-388: Roche’s GLP-1/GIP dual agonist and the Carmot acquisition
CT-388 is a GLP-1/GIP dual agonist originally developed by Carmot Therapeutics and subsequently brought into Roche’s pipeline through acquisition — making the Carmot deal a significant IP and pipeline event for the obesity space. CT-388 is designed as a subcutaneous injectable that co-activates both the glucagon-like peptide-1 receptor and the glucose-dependent insulinotropic polypeptide receptor, a mechanism that tirzepatide (Eli Lilly) has already validated at the clinical and commercial level.
CT-388 is also known by the regulatory and clinical database identifier RO7624942. When searching USPTO, EPO, WIPO, or ClinicalTrials.gov, using this compound identifier alongside the assignee name “Roche Holdings AG” or “Carmot Therapeutics” will return the most complete set of relevant filings and registrations.
The strategic logic of the Roche/Carmot transaction is clear: rather than building GLP-1/GIP co-agonism chemistry from scratch, Roche acquired a program with existing composition-of-matter IP, a clinical data package, and a differentiated peptide scaffold. For IP teams tracking freedom-to-operate in this space, the Carmot acquisition means that CT-388’s patent estate — covering receptor selectivity ratios, peptide sequence claims, and formulation approaches — is now consolidated under Roche’s portfolio and subject to Roche’s prosecution strategy at the EPO and USPTO.
“CT-388’s weight reduction benchmarks versus tirzepatide, and Roche’s acquisition of Carmot Therapeutics as an IP and pipeline event, are among the most closely watched signals in obesity drug development.”
Tracking CT-388’s clinical development requires monitoring multiple data streams simultaneously: IND filings, Phase II interim data releases, Phase III design disclosures, and regulatory pathway signals. Conference presentations at ADA (American Diabetes Association), ENDO (Endocrine Society), and ObesityWeek are primary venues where early efficacy and tolerability data are disclosed ahead of peer-reviewed publication. SEC filings from Roche also contain pipeline milestone disclosures that precede public clinical data.
Track CT-388 patent filings, Carmot acquisition IP, and the full Roche obesity pipeline in real time.
Explore CT-388 Patent Data in PatSnap Eureka →Petrelintide: Zealand Pharma’s amylin bet on a distinct neuroendocrine pathway
Petrelintide is Zealand Pharma’s amylin/calcitonin receptor agonist for obesity — a program mechanistically distinct from every incretin-based approach in the competitive landscape. Where CT-388, tirzepatide, and triple agonists all operate through the incretin axis (GLP-1, GIP, and/or glucagon receptors), petrelintide targets the amylin receptor system, which regulates satiety through a separate neuroendocrine pathway originating in the pancreatic beta cell.
Petrelintide is Zealand Pharma’s amylin/calcitonin receptor agonist for obesity. Unlike GLP-1/GIP dual agonists such as CT-388 and tirzepatide, petrelintide acts on a distinct neuroendocrine pathway and has potential for combination use with GLP-1 agonists, offering a differentiated positioning strategy in the obesity pharmacotherapy market.
This mechanistic distinction creates a strategic opening that Zealand Pharma is explicitly pursuing: petrelintide may be positioned not only as a standalone therapy but as a combination partner for existing GLP-1 agonists. The hypothesis is that additive or synergistic weight loss could be achieved by simultaneously targeting the incretin and amylin pathways — a combination that neither tirzepatide nor CT-388 can replicate within a single molecule.
Petrelintide’s amylin/calcitonin receptor mechanism creates potential for combination with GLP-1 agonists that GLP-1/GIP dual agonists cannot offer. This positions Zealand Pharma’s program as both a standalone obesity therapy and a potential combination partner in a multi-drug treatment paradigm — a differentiation strategy with distinct IP implications for formulation and combination patents.
From an IP perspective, Zealand Pharma’s amylin receptor approach generates a patent estate that is structurally separate from the incretin IP held by Roche, Eli Lilly, and Novo Nordisk. Composition-of-matter claims covering the petrelintide peptide sequence, receptor binding profiles, and formulation strategies are filed under assignee “Zealand Pharma A/S” and can be located using IPC code A61K38/26 (peptide hormones) in combination with A61P3/04 (anti-obesity agents) at patent offices including WIPO.
Clinical data for petrelintide is disclosed primarily at major endocrinology and metabolism conferences, including ObesityWeek, and through Zealand Pharma’s corporate pipeline disclosures. Preprint servers such as bioRxiv and medRxiv are increasingly important early-disclosure venues for translational data in this space, as noted by researchers publishing through Nature portfolio journals covering metabolic disease.
Competitive dynamics: dual agonism versus amylin versus triple agonism
The competitive differentiation across GLP-1/GIP dual agonism (CT-388, tirzepatide), amylin receptor agonism (petrelintide), and triple agonism (GLP-1/GIP/glucagon) turns on three dimensions: efficacy depth, tolerability profile, and dosing convenience. Each mechanistic category presents a different risk-benefit hypothesis that will ultimately be adjudicated by Phase III head-to-head data and regulatory review.
GLP-1/GIP dual agonism has the advantage of a validated proof-of-concept via tirzepatide’s commercial success. CT-388 must therefore demonstrate either superior efficacy, a more favourable tolerability profile, or a meaningfully differentiated dosing regimen to justify market positioning alongside tirzepatide. Roche’s acquisition of Carmot Therapeutics signals confidence that the CT-388 peptide scaffold can deliver at least one of these differentiation vectors.
Triple agonism — targeting GLP-1, GIP, and glucagon receptors simultaneously — represents the highest-efficacy hypothesis in the space, with programs from Eli Lilly and Novo Nordisk in active development. The trade-off is tolerability: glucagon receptor activation introduces hepatic and cardiovascular complexity that dual agonists avoid. For IP teams, the triple agonist landscape generates a distinct patent cluster around glucagon receptor selectivity claims that is structurally separate from the CT-388 and petrelintide estates.
The competitive differentiation across GLP-1/GIP dual agonism (CT-388, tirzepatide), amylin receptor agonism (petrelintide), and GLP-1/GIP/glucagon triple agonism in obesity pharmacotherapy turns on three dimensions: efficacy depth, tolerability profile, and dosing convenience. Each mechanistic category generates a structurally distinct patent estate covering receptor selectivity claims, peptide sequences, and formulation strategies.
Map the full competitive patent landscape across GLP-1/GIP, amylin, and triple agonist obesity programs.
Analyse Obesity Pipeline Patents in PatSnap Eureka →Patent intelligence: how to map the CT-388 and petrelintide IP landscape
Generating a complete patent intelligence picture for the CT-388 and petrelintide programs requires a multi-vector search strategy across compound identifiers, assignee names, and IPC/CPC classification codes. Relying on any single search dimension will produce an incomplete picture of the competitive IP environment.
Compound and assignee identifiers
For CT-388, the primary search identifiers are: the compound name “CT-388”, the regulatory identifier “RO7624942”, and the assignee names “Carmot Therapeutics” and “Roche Holdings AG”. These should be applied across USPTO, EPO, and WIPO patent databases as well as ClinicalTrials.gov for trial registrations. For petrelintide, the INN “petrelintide” and the assignee “Zealand Pharma A/S” are the primary search anchors.
IPC/CPC classification codes
The two most relevant patent classification codes for this pipeline are A61K38/26 (peptide hormones, including GLP-1 analogs and related incretin peptides) and A61P3/04 (anti-obesity agents). These codes, used in combination with assignee filters, will surface composition-of-matter claims, formulation patents, and receptor selectivity claims filed by Roche, Zealand Pharma, Eli Lilly, and Novo Nordisk — the four major assignees competing in this space.
Broadening beyond patent databases
A complete intelligence picture for this space requires data sources beyond patent filings alone. ClinicalTrials.gov records provide IND filing dates and trial design disclosures. SEC filings from Roche and Zealand Pharma contain pipeline milestone language. Conference abstracts from ADA, ENDO, and ObesityWeek provide early efficacy signals. Preprint servers bioRxiv and medRxiv host translational data ahead of peer-reviewed publication. According to WHO classifications, obesity is a chronic disease requiring long-term pharmacological management, which underpins the regulatory rationale for multiple competing mechanisms in this space.
Roche Holdings AG (CT-388/Carmot), Zealand Pharma A/S (petrelintide), Eli Lilly and Company (tirzepatide, retatrutide), and Novo Nordisk A/S (semaglutide, triple agonist programs) are the four primary assignees whose patent filings define the competitive IP landscape in next-generation obesity pharmacotherapy. Monitoring all four simultaneously is essential for freedom-to-operate analysis and white-space identification.
For R&D intelligence teams working on obesity drug discovery, the PatSnap Life Sciences platform aggregates patent data, clinical trial records, and literature signals into a single searchable environment — enabling the kind of multi-vector search strategy that this competitive landscape demands. PatSnap serves over 18,000 customers across 120+ countries, with access to more than 2 billion data points spanning patents, clinical trials, and scientific literature. Learn more about PatSnap’s innovation intelligence research covering drug discovery and IP strategy.